EpimAb Biotherapeutics is an innovative biotech company focusing on developing next generation antibody-based technologies and break-through biologic therapies.
EpimAb Biotherapeutics is dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
EpimAb Biotherapeutics was founded in 2015 by Chengbin Wu and is based in Shanghai, Shanghai, China.
EpimAb Biotherapeutics uses a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.
EpimAb is further committed to diversifying its portfolio of FIT-Igs together with partners in order to further validate the flexibility and robustness of the format and its platform.
EpimAb is backed by Sherpa Venture Capital, SDIC Fund Management, Oriza Seed Capital (Oriza Yuandian), South China Venture Capital and others.